Living Cell Technologies Ltd. (AU:1AI)
ASX:1AI
Top Page
Living Cell Technologies
(Sydney:1AI)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.02
â–¼(-25.00% Downside)
Action:ReiteratedDate:03/12/26
The score is weighed down primarily by weak financial performance (no revenue, sustained losses, and negative free cash flow) despite the benefit of having no debt. Technical indicators also remain bearish with the stock below key moving averages and negative MACD, while valuation signals are limited due to a negative P/E and no dividend support.
Positive Factors
Low leverage / No debt
The company’s lack of debt materially lowers financing costs and bankruptcy risk, preserving financial flexibility. For a development-stage biotech, no interest burden extends runway between fundraises, reduces fixed cash obligations, and improves negotiating leverage with partners or acquirers over the medium term.
Negative Factors
Lack of revenue
Effectively zero commercial revenue means the business remains dependent on external financing, grants, or partnerships to fund R&D and operations. This structural absence of recurring income increases execution risk, makes planning sensitive to capital markets access, and elevates dilution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / No debt
The company’s lack of debt materially lowers financing costs and bankruptcy risk, preserving financial flexibility. For a development-stage biotech, no interest burden extends runway between fundraises, reduces fixed cash obligations, and improves negotiating leverage with partners or acquirers over the medium term.
Read all positive factors
Living Cell Technologies (1AI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$28.18M
Dividend YieldN/A
Average Volume (3M)2.98M
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,761,032,200
10 Day Avg. Volume1,972,597
30 Day Avg. Volume2,982,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Living Cell Technologies Business Overview & Revenue Model
Company Description
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-c...
How the Company Makes Money
null...
Living Cell Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2024 | Jun 2024 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -557.00 | -743.00 | -49.31K |
| EBITDA | -2.04M | -1.54M | -2.10M | -2.13M | -2.38M | -1.86M |
| Net Income | -1.01M | -802.96K | -2.10M | -2.11M | -1.96M | -1.46M |
Balance Sheet | ||||||
| Total Assets | 2.00M | 2.40M | 5.49M | 6.23M | 4.27M | 1.64M |
| Cash, Cash Equivalents and Short-Term Investments | 1.88M | 2.32M | 3.11M | 6.13M | 7.24M | 1.61M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 111.25K | 169.76K | 178.45K | 449.86K | 239.26K | 265.08K |
| Stockholders Equity | 1.89M | 2.23M | 3.01M | 3.76M | 4.03M | 1.38M |
Cash Flow | ||||||
| Free Cash Flow | -702.90K | -785.25K | -1.52M | -1.99M | -2.05M | -1.46M |
| Operating Cash Flow | -702.90K | -785.25K | -1.52M | -1.99M | -2.04M | -1.46M |
| Investing Cash Flow | 1.35M | 450.00K | -277.44K | 0.00 | 39.50K | 105.86K |
| Financing Cash Flow | 179.59K | -3.00K | 523.00K | 1.85M | 4.69M | -44.54K |
Living Cell Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$7.52M | -3.15 | -17.07% | ― | ― | 71.10% | |
46 Neutral | AU$33.26M | -5.38 | -19.10% | ― | ― | -672.73% | |
45 Neutral | AU$8.84M | -0.15 | 2844.96% | ― | ― | 46.28% | |
45 Neutral | AU$12.81M | -1.59 | -91.88% | ― | -93.83% | 20.00% | |
43 Neutral | AU$28.18M | -6.84 | -49.25% | ― | ― | ― | |
43 Neutral | AU$11.21M | -1.00 | -218.76% | ― | ― | ― |
* Healthcare Sector Average
AU:1AI
Living Cell Technologies
0.02
<0.01
60.00%
AU:IXC
Invex Therapeutics Ltd.
0.10
0.03
49.25%
AU:CMB
Regeneus Ltd.
0.41
0.13
46.43%
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.10
0.06
150.00%
AU:MEM
Memphasys Ltd
―
―
―
Living Cell Technologies Corporate Events
Algorae Pharmaceuticals Plans Major Share and Option Issue
Apr 2, 2026
Algorae Pharmaceuticals has outlined plans for a new capital raising via a placement or similar issue of securities on the ASX. The company intends to issue up to 89,350,001 fully paid ordinary shares and 11,000,000 options exercisable at $0.014 e...
Algorae Pharmaceuticals Bolsters Balance Sheet with $3.99m Capital Raise
Apr 2, 2026
Algorae Pharmaceuticals has raised approximately $3.99 million before costs through the exercise of listed options and a shortfall placement to sophisticated, long-term shareholders at a discounted issue price. The funding lifts the company’...
Algorae Wins TGA Dossier Acceptance for First Generic Medicine
Apr 1, 2026
Algorae Pharmaceuticals has had its initial registration dossier accepted for evaluation by Australia’s Therapeutic Goods Administration, marking an early but important milestone in progressing its first product toward potential commercialis...
Algorae Pharmaceuticals Issues Cleansing Notice for Newly Issued Shares
Mar 27, 2026
Algorae Pharmaceuticals has issued new fully paid ordinary shares, as reflected in an Appendix 2A lodged on the ASX, and has confirmed that these securities were issued without the need for a prospectus or disclosure document under Part 6D.2 of th...
Algorae Pharmaceuticals Seeks ASX Quotation for 44 Million New Shares
Mar 27, 2026
Algorae Pharmaceuticals Limited has applied for quotation on the ASX of 44,241,067 new fully paid ordinary shares under its ticker 1AI. The new securities, issued on March 27, 2026, expand the company’s quoted share capital and may enhance i...
Algorae boosts AlgoraeRx sales leadership with hospital market veteran
Mar 19, 2026
Algorae Pharmaceuticals has appointed veteran pharmaceutical executive Waleed Elsayed as Head of Sales for its commercial arm AlgoraeRx, reinforcing its leadership bench as it pushes to scale in the Australian and New Zealand hospital markets. Els...
Algorae Pharmaceuticals Seeks ASX Quotation for 3.85 Million New Shares
Mar 13, 2026
Algorae Pharmaceuticals has applied to the ASX for quotation of 3,852,712 additional ordinary fully paid shares, to be issued on March 13, 2026. The move increases the company’s quoted share capital, potentially enhancing liquidity for inves...
Algorae Pharmaceuticals Issues 30 Million Unquoted Long-Dated Options
Mar 13, 2026
Algorae Pharmaceuticals has notified the market of the issue of 30 million unquoted options, each exercisable at $0.014 and expiring on 1 December 2029. The options, recorded under ASX security code 1AIAT, form part of a previously announced trans...
Algorae Pharmaceuticals Names New Director, Details Indirect Equity Stakes
Mar 12, 2026
Algorae Pharmaceuticals has appointed David Gulland as a director effective 10 March 2026, and lodged an initial director’s interest notice stating he holds no shares or options in his own name. The filing discloses that his relevant interes...
Algorae Pharmaceuticals Discloses Final Interests of Departing Director
Mar 12, 2026
Algorae Pharmaceuticals has announced that director Bradley Latham has ceased to be a director of the company as of 10 March 2026. The company disclosed his final interests, including 20,000,000 ordinary shares, multiple tranches of performance ri...
Algorae Pharmaceuticals strengthens board with appointment of industry veteran David Gulland
Mar 9, 2026
Algorae Pharmaceuticals has appointed senior industry executive David Gulland as a Non-Executive Director, adding more than 20 years of experience in wholesale pharmaceuticals, private healthcare funding and pharmacy services at a time when the co...
Algorae Pharmaceuticals Issues 42 Million Performance Rights Under Incentive Scheme
Mar 5, 2026
Algorae Pharmaceuticals has issued 42,000,000 unquoted performance rights under its employee incentive scheme, effective 5 March 2026. The large grant of performance rights underscores the company’s reliance on equity-based remuneration to i...
Algorae Director Boosts Indirect Stake Through Option Exercise
Mar 5, 2026
Algorae Pharmaceuticals has disclosed a change in director David Hainsworth’s interests following the exercise of options through his controlled entity Union Square Capital Pty Ltd. The transaction saw the conversion of 312,500 options into ...
Algorae Pharmaceuticals Issues New Shares Under Cleansing Notice
Mar 5, 2026
Algorae Pharmaceuticals has issued new fully paid ordinary shares, as detailed in an Appendix 2A lodged with the ASX, and has done so without a prospectus under the disclosure exemptions of the Corporations Act. The company confirms it is up to da...
Algorae Pharmaceuticals Seeks ASX Quotation for 5.06 Million New Shares
Mar 5, 2026
Algorae Pharmaceuticals Limited has applied to the ASX for quotation of 5,062,500 new ordinary fully paid shares under the code 1AI, with an issue date of March 5, 2026. The additional quoted securities, arising from the exercise or conversion of ...
Algorae Pharmaceuticals Issues New Shares and Confirms Regulatory Compliance
Feb 27, 2026
Algorae Pharmaceuticals has issued new fully paid ordinary shares, as detailed in a contemporaneous Appendix 2A lodgement, and has confirmed that these securities were issued without a prospectus under the Act’s disclosure exemptions. The co...
Algorae Pharmaceuticals Seeks ASX Quotation for 7.4 Million New Shares
Feb 27, 2026
Algorae Pharmaceuticals Limited has applied to the Australian Securities Exchange for quotation of 7,377,816 new ordinary fully paid shares under its existing ticker 1AI. The new securities, issued on February 27, 2026, arise from the exercise or ...
Algorae Pharmaceuticals Files Half-Year Report and Highlights Dual AI and Commercial Focus
Feb 27, 2026
Algorae Pharmaceuticals has released its half-year report for the six months ended 31 December 2025, providing the market with an update on its activities and financial performance over the period. The announcement, approved by the board, undersco...
Algorae expands ANZ generics portfolio with Cadila cardiovascular and metabolic deal
Feb 8, 2026
Algorae Pharmaceuticals has signed a definitive licence and supply agreement with India’s Cadila Pharmaceuticals to launch two generic medicines for cardiovascular and metabolic disorders in Australia and New Zealand. Under the deal, Cadila ...
Algorae Issues Confidential Non-Deal Investor Presentation with Strong Risk Disclaimers
Feb 2, 2026
Algorae Pharmaceuticals has released a February 2026 non-deal investor presentation outlining general information about the company and its activities, while emphasising that the document is for informational purposes only and does not constitute ...
Algorae Pharmaceuticals Seeks ASX Quotation for 47,745 New Shares
Feb 2, 2026
Algorae Pharmaceuticals Limited has applied to the ASX for quotation of 47,745 new fully paid ordinary shares under its ticker 1AI, issued on 2 February 2026 following the exercise of options or conversion of other securities. The modest increase ...
Algorae Pharmaceuticals Advances AI Drug Platform and Oncology Commercial Push
Jan 27, 2026
Algorae Pharmaceuticals reported strong progress for the December 2025 quarter, highlighted by a new distribution agreement with Dr. Reddy’s Laboratories for Capecitabine 500mg tablets that marks a key step toward oncology revenue in Austral...
Algorae Secures A$3m ScotPac Facility to Scale ANZ Commercial Operations
Jan 20, 2026
Algorae Pharmaceuticals has secured a A$3.0 million receivables-based working capital facility from ScotPac Business Finance for an initial 24-month term, providing a revolving, non-dilutive source of funding that can be drawn and repaid flexibly ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.